Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

School program to help children continue normal educational activities during treatment

Treatment for cancer and other catastrophic disease can last months or years and often makes it impossible for young patients to keep up with their local school curriculum. Teachers in the St. Jude School Program Presented by Target help patients continue their normal educational activities while away from their local schools. They are also part of the health care team that provides opportunities to continue normal educational activities through homebound or hospital-bound educational services. In addition, the team provides school re-entry services to ease the transition back to the community school.

26 Jul 2010

Experimental treatment for sickle cell disease enters Phase 3 clinical trials

An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.

26 Jul 2010

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

A Johns Hopkins University scientist, whose team of researchers recently identified pneumonia, diarrhea, and malaria as the primary causes of death of 6 million of the world's poorest children, today called on leaders in donor and developing nations to take action to address the terrible death toll.

23 Jul 2010

New drug to treat chronic pain in SCD patients

A University of Minnesota Medical School research team led by Kalpna Gupta, Ph.D., has discovered that cannibinoids offer a novel approach to ease the chronic and acute pain caused by sickle cell disease.Using a mouse model of SCD, Gupta and University of Minnesota colleagues studied the pain mechanisms by observing animals that exhibited both musculoskeletal pain and temperature sensitivity, symptoms similarly experienced by humans with SCD. The team compared two classifications of drugs in their ability to manage pain sensed by the animals, the traditionally prescribed classification of drugs, opioids, with a new therapeutic approach, cannabinoids, a synthetic compound based on marijuana derivatives. Currently, the only approved treatment for management of severe pain in SCD is opioids.

23 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

20 Jul 2010

Two patents issued for GlycoMimetics lead drug candidate, related compounds

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.

15 Jul 2010

St. Jude Children's Research Hospital ranked among top 10 "Best Places to Work in Academia"

St. Jude Children's Research Hospital is ranked as one of the top institutions in the annual "Best Places to Work in Academia" list by The Scientist magazine. This is the fifth consecutive year St. Jude made the publication's top 10 list of institutions in the United States. The hospital ranks second in the country behind Princeton University.

29 Jun 2010

Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.

25 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

FerroKin BioSciences announces closing of $12M financing

FerroKin BioSciences, a biotechnology company developing a new therapy for the treatment of iron overload, today announced the closing of a $12 million financing. Participants in the financing include current investors Burrill & Company, Celgene Corporation, Clarus Ventures and MP Healthcare Venture Management, Inc., with Healthcap Ventures of Stockholm participating as a new investor.

18 Jun 2010

Constipation prophylaxis in sickle cell patients needs increased attention

Not all patients with sickle cell disease receive laxatives after being treated with narcotics, despite recommendations from a collaborative panel of pediatric experts. These are the findings from a Nationwide Children's Hospital study examining patients from 29 pediatric hospitals, and appearing in Pediatric Blood & Cancer.

17 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Children get MRI tests for reasons unrelated to benign anomalies: Study

Pediatricians whose patients undergo "routine" brain MRIs need a plan to deal with findings that commonly reveal unexpected-but-benign anomalies that are unlikely to cause any problem, reports a research team led by Johns Hopkins Children's Center investigators.

14 Jun 2010

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

10 Jun 2010

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.

8 Jun 2010

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.

5 Jun 2010

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Faculty at the Johns Hopkins Berman Institute of Bioethics have published a study that shows, among adults with sickle cell disease, that unsatisfactory interactions with health-care providers in the past affect their trust in the medical profession more broadly.

5 Jun 2010

St. Jude receives top spot in 2010-11 Best Children's Hospital rankings

St. Jude Children's Research Hospital has been named the nation's top children's cancer hospital in the 2010-11 Best Children's Hospital rankings published in U.S. News & World Report. St. Jude received the best overall score summarizing quality of care. St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children and serves as an international resource to physicians and researchers.

4 Jun 2010

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

School program to help children continue normal educational activities during treatment

Experimental treatment for sickle cell disease enters Phase 3 clinical trials

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

New drug to treat chronic pain in SCD patients

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Two patents issued for GlycoMimetics lead drug candidate, related compounds

St. Jude Children's Research Hospital ranked among top 10 "Best Places to Work in Academia"

Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated

Risk, incidence of VTE differs between races

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

FerroKin BioSciences announces closing of $12M financing

Constipation prophylaxis in sickle cell patients needs increased attention

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Children get MRI tests for reasons unrelated to benign anomalies: Study

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

St. Jude receives top spot in 2010-11 Best Children's Hospital rankings

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in